Rhythm Pharmaceuticals Inc.
RYTM
Market Cap$2.67B
Close$
$-24.80
160.5% downside
Current Fair Value
160.5% downsideOvervalued by 160.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.67 Billion |
|---|---|
| Enterprise Value | $2.50 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-3.2 |
| Beta | 1.31 |
| Outstanding Shares | 60,972,909 |
| Avg 30 Day Volume | 520,518 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -14.45 |
|---|---|
| PEG | 713.87 |
| Price to Sales | 40.98 |
| Price to Book Ratio | 20.49 |
| Enterprise Value to Revenue | 32.28 |
| Enterprise Value to EBIT | -13.56 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.63 |
Revenue Sources
No data
ESG Score
No data
About Rhythm Pharmaceuticals Inc.
90 employees
CEO: Hunter Smith Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within the mel...